{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:42Z","timestamp":1793272782742,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell\u2019Aquila","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to quantitatively assess the effectiveness of tamoxifen, anastrozole, and radiotherapy in preventing bicalutamide-induced breast events\u2014specifically gynecomastia and breast pain\u2014in patients with prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA-P guidelines. A comprehensive search was performed in PubMed, Scopus, and Web of Science for English-language studies without temporal restrictions. Studies were included if they involved prostate cancer patients treated with bicalutamide receiving preventive interventions (tamoxifen, anastrozole, or radiotherapy) compared to bicalutamide alone (or bicalutamide plus placebo\/sham). Data extraction focused on the incidence of gynecomastia and breast pain, and study quality was assessed using the Jadad scale. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models, and heterogeneity was evaluated with the I\u00b2 statistic. Publication bias was explored via funnel plots and the trim-and-fill method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nine RCTs met the inclusion criteria. Tamoxifen significantly reduced the risk of breast events by 82% (RR: 0.18, 95% CI: 0.08\u20130.38 for gynecomastia and RR: 0.18, 95% CI: 0.07\u20130.43 for breast pain). Radiotherapy reduced gynecomastia risk by 52% (RR: 0.48, 95% CI: 0.38\u20130.59) and breast pain by 34% (RR: 0.66, 95% CI: 0.48\u20130.90). Anastrozole did not show significant benefit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tamoxifen appears to be the most effective strategy for preventing bicalutamide-induced breast events, with radiotherapy serving as a viable alternative, and anastrozole offering no benefit. Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-025-02583-8","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:19:04Z","timestamp":1744856344000},"page":"1659-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"48","author":[{"given":"Luca","family":"Spagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-7955","authenticated-orcid":false,"given":"Daniele","family":"Tienforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Puocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Barbonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2583_CR1","doi-asserted-by":"publisher","unstructured":"Perdon\u00e0 S, Autorino R, De Placido S, D\u2019Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol.;6(5):295\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(05)70103-0. PMID: 15863377","DOI":"10.1016\/S1470-2045(05)70103-0"},{"issue":"2","key":"2583_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/cancers17020194","volume":"17","author":"H Mallah","year":"2025","unstructured":"Mallah H, Diabasana Z, Soultani S, Idoux-Gillet Y, Massfelder T (2025) Prostate cancer: A journey through its history and recent developments. Cancers (Basel) 17(2):194. https:\/\/doi.org\/10.3390\/cancers17020194PMID: 39857976; PMCID: PMC11763992","journal-title":"Cancers (Basel)"},{"key":"2583_CR3","doi-asserted-by":"publisher","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Powell P, Rosario DJ, Rowe E, Mason M, Catto JWF, Peters TJ, Oxley J, Williams NJ, Staffurth J, Neal DE (2023) ProtecT Study Group. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med.;388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122. Epub 2023 Mar 11. PMID: 36912538","DOI":"10.1056\/NEJMoa2214122"},{"issue":"12","key":"2583_CR4","doi-asserted-by":"publisher","first-page":"16773","DOI":"10.18632\/aging.203198","volume":"13","author":"F Wang","year":"2021","unstructured":"Wang F, Fan Y, Yin X, Qi LW, Ma G, Yuan Q (2021) Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages. Aging 13(12):16773\u201316785. https:\/\/doi.org\/10.18632\/aging.203198Epub 2021 Jun 29. PMID: 34185023; PMCID: PMC8266375","journal-title":"Aging"},{"key":"2583_CR5","doi-asserted-by":"publisher","unstructured":"Iversen P (2002) Antiandrogen monotherapy: indications and results. Urology.;60(3 Suppl 1):64\u201371. https:\/\/doi.org\/10.1016\/s0090-4295(02)01576-5. PMID: 12231053","DOI":"10.1016\/s0090-4295(02)01576-5"},{"key":"2583_CR6","doi-asserted-by":"publisher","unstructured":"Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol.;23(4):808\u2013\u200915. https:\/\/doi.org\/10.1200\/JCO.2005.12.013. PMID: 15681525","DOI":"10.1200\/JCO.2005.12.013"},{"issue":"2","key":"2583_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvi\u00e8re O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027Epub 2024 Apr 13. PMID: 38614820","journal-title":"Eur Urol"},{"key":"2583_CR8","doi-asserted-by":"publisher","unstructured":"See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T (2003) Immediate treatment with bicalutamide 150\u00a0mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol.;44(5):512-7; discussion 517-8. https:\/\/doi.org\/10.1016\/s0302-2838(03)00366-x. PMID: 14572747","DOI":"10.1016\/s0302-2838(03)00366-x"},{"key":"2583_CR9","doi-asserted-by":"publisher","unstructured":"Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Casodex Early Prostate Cancer Trialists\u2019 Group. Bicalutamide 150\u00a0mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol.;172(5 Pt 1):1865-70. https:\/\/doi.org\/10.1097\/01.ju.0000140159.94703.80. PMID: 15540740","DOI":"10.1097\/01.ju.0000140159.94703.80"},{"key":"2583_CR10","doi-asserted-by":"crossref","unstructured":"See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group (2002). Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol.;168(2):429\u2013\u200935. Erratum in: J Urol 2002;168(6):2558. Erratum in: J Urol 2002;168;4(Pt 1):1510. PMID: 12131282","DOI":"10.1016\/S0022-5347(05)64652-6"},{"key":"2583_CR11","doi-asserted-by":"publisher","unstructured":"Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP (2010) Casodex Early Prostate Cancer Trialists\u2019 Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int.;105(8):1074-81. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09319.x. PMID: 22129214","DOI":"10.1111\/j.1464-410X.2010.09319.x"},{"key":"2583_CR12","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: [Prostate Cancer] Version [3.2024]. 2024. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"6","key":"2583_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S, ESMO Guidelines Committee (2023) Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents. Ann Oncol 34(6):557\u2013563 Epub 2023 Mar 21. PMID: 36958590","journal-title":"Ann Oncol"},{"issue":"2","key":"2583_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders JLH, Liew G, Linares Espinos M, Oldenburg E, van Oort J, Oprea-Lager IM, Ploussard DE, Roberts G, Rouvi\u00e8re MJ, Schoots O, Schouten IG, Smith N, Stranne EJ, Wiegel J, Willemse T, Cornford PM (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86(2):164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010Epub 2024 Apr 29. PMID: 38688773","journal-title":"Eur Urol"},{"issue":"3","key":"2583_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41391-024-00829-9","volume":"27","author":"M Shelan","year":"2024","unstructured":"Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R (2024) Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis 27(3):422\u2013431. https:\/\/doi.org\/10.1038\/s41391-024-00829-9Epub 2024 Apr 8. PMID: 38589645; PMCID: PMC11319196","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"2583_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1590\/s1516-31802012000300009","volume":"130","author":"AC Barros","year":"2012","unstructured":"Barros AC, Sampaio Mde C (2012) Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Med J 130(3):187\u2013197. https:\/\/doi.org\/10.1590\/s1516-31802012000300009PMID: 22790552; PMCID: PMC10876201","journal-title":"Sao Paulo Med J"},{"key":"2583_CR17","first-page":"1","volume":"25","author":"JD Wilson","year":"1980","unstructured":"Wilson JD, Aiman J, MacDonald PC (1980) The pathogenesis of gynecomastia. Adv Intern Med 25:1\u201332 PMID: 6987837","journal-title":"Adv Intern Med"},{"key":"2583_CR18","doi-asserted-by":"publisher","unstructured":"Mathur R, Braunstein GD (1997) Gynecomastia: pathomechanisms and treatment strategies. Horm Res.;48(3):95\u2013102. https:\/\/doi.org\/10.1159\/000185497. PMID: 11546925","DOI":"10.1159\/000185497"},{"issue":"8","key":"2583_CR19","doi-asserted-by":"publisher","first-page":"e0136094","DOI":"10.1371\/journal.pone.0136094","volume":"10","author":"A Fagerlund","year":"2015","unstructured":"Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G (2015) Gynecomastia in patients with prostate cancer: A systematic review. PLoS ONE 10(8):e0136094. https:\/\/doi.org\/10.1371\/journal.pone.0136094PMID: 26308532; PMCID: PMC4550398","journal-title":"PLoS ONE"},{"issue":"2","key":"2583_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/2230-8210.129104","volume":"18","author":"N Cuhaci","year":"2014","unstructured":"Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B, Gynecomastia (2014) Clinical evaluation and management. Indian J Endocrinol Metab 18(2):150\u2013158. https:\/\/doi.org\/10.4103\/2230-8210.129104PMID: 24741509; PMCID: PMC3987263","journal-title":"Indian J Endocrinol Metab"},{"key":"2583_CR21","doi-asserted-by":"publisher","unstructured":"Sieber PR (2007) Treatment of bicalutamide-induced breast events. Expert Rev Anticancer Ther.;7(12):1773-9. https:\/\/doi.org\/10.1586\/14737140.7.12.1773. PMID: 18062751","DOI":"10.1586\/14737140.7.12.1773"},{"key":"2583_CR22","unstructured":"Swerdloff RS, Ng JCM, Gynecomastia: Etiology, Diagnosis (2023) and Treatment. Jan 6. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u2013. PMID: 25905330"},{"key":"2583_CR23","doi-asserted-by":"publisher","unstructured":"Tyrrell CJ (1999) Gynaecomastia: aetiology and treatment options. Prostate Cancer Prostatic Dis.;2(4):167\u2013171. https:\/\/doi.org\/10.1038\/sj.pcan.4500314. PMID: 12496773","DOI":"10.1038\/sj.pcan.4500314"},{"key":"2583_CR24","doi-asserted-by":"publisher","unstructured":"Di Lorenzo G, Perdon\u00e0 S, De Placido S, D\u2019Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R (2005) Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol.;174(6):2197\u2013\u2009203. https:\/\/doi.org\/10.1097\/01.ju.0000181824.28382.5c. PMID: 16280763","DOI":"10.1097\/01.ju.0000181824.28382.5c"},{"key":"2583_CR25","doi-asserted-by":"crossref","unstructured":"Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (2007) Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150\u00a0mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol.;52(1):106\u2013\u200914. doi: 10.1016\/j.eururo.2007.01.031. Epub 2007 Jan 16. PMID: 17270340","DOI":"10.1016\/j.eururo.2007.01.031"},{"key":"2583_CR26","doi-asserted-by":"publisher","unstructured":"Saltzstein D, Sieber P, Morris T, Gallo J (2005) Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis.;8(1):75\u201383. https:\/\/doi.org\/10.1038\/sj.pcan.4500782. PMID: 15685254","DOI":"10.1038\/sj.pcan.4500782"},{"key":"2583_CR27","doi-asserted-by":"crossref","unstructured":"Serretta V, Altieri V, Morgia G, Nicolosi F, De Grande G, Mazza R, Melloni D, Allegro R, Ferra\u00f9 F, Gebbia V (2012) A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer.;10(3):174-9. doi: 10.1016\/j.clgc.2012.03.002. Epub 2012 Apr 12. PMID: 22502790","DOI":"10.1016\/j.clgc.2012.03.002"},{"issue":"2","key":"2583_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.juro.2010.03.137","volume":"184","author":"H Ozen","year":"2010","unstructured":"Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, Abay E, Cureklibatur I, Sengoz M, Yalcin V, Akpinar H, Zorlu F, Sengor F, Karaman I (2010) Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and\/or breast pain? J Urol 184(2):519\u2013524 Epub 2010 Jun 17. PMID: 20620411","journal-title":"J Urol"},{"key":"2583_CR29","doi-asserted-by":"publisher","unstructured":"Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys.;60(2):476\u2013\u200983. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.03.022. PMID: 15380582","DOI":"10.1016\/j.ijrobp.2004.03.022"},{"key":"2583_CR30","doi-asserted-by":"publisher","unstructured":"Widmark A, Foss\u00e5 SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O (2003) Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7\/SFUO-3. Urology.;61(1):145\u2013\u200951. https:\/\/doi.org\/10.1016\/s0090-4295(02)02107-6. PMID: 12559286","DOI":"10.1016\/s0090-4295(02)02107-6"},{"issue":"7","key":"2583_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","volume":"196","author":"P Ghadjar","year":"2020","unstructured":"Ghadjar P, Aebersold DM, Albrecht C, B\u00f6hmer D, Flentje M, Ganswindt U, H\u00f6cht S, H\u00f6lscher T, M\u00fcller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T, Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO), The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO) (2020) Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol 196(7):589\u2013597. https:\/\/doi.org\/10.1007\/s00066-020-01598-9Epub 2020 Mar 12. PMID: 32166452; PMCID: PMC7305090","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"2583_CR32","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.3747\/co.19.993","volume":"19","author":"MA Tunio","year":"2012","unstructured":"Tunio MA, Al-Asiri M, Al-Amro A, Bayoumi Y, Fareed M (2012) Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis. Curr Oncol 19(4):e280\u2013e288. https:\/\/doi.org\/10.3747\/co.19.993PMID: 22876157; PMCID: PMC3410840","journal-title":"Curr Oncol"},{"issue":"1","key":"2583_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"issue":"1","key":"2583_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"2583_CR35","first-page":"1539","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. StatMed 21:1539\u20131558","journal-title":"StatMed"},{"issue":"7304","key":"2583_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","volume":"323","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101\u2013105. https:\/\/doi.org\/10.1136\/bmj.323.7304.101PMID: 11451790; PMCID: PMC1120714","journal-title":"BMJ"},{"key":"2583_CR37","first-page":"89","volume":"95","author":"SJ Duval","year":"2000","unstructured":"Duval SJ, Tweedie RL (2000) A non-parametric trim and fill method of assessing publication bias in meta-analysis. J Am Stat Assoc 95:89\u201398","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"2583_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S, ESMO Guidelines Committee (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011","journal-title":"Ann Oncol"},{"key":"2583_CR39","unstructured":"Cornford P, Tilki D, van den Bergh RCN et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u2013 Limited Update April 2024. Eur Urol. Available at: https:\/\/uroweb.org\/guideline\/prostate-cancer. Accessed March 12, 2025"},{"key":"2583_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2025.01.001","volume":"73","author":"I Tsuboi","year":"2025","unstructured":"Tsuboi I, Schulz RJ, Laukhtina E, Wada K, Karakiewicz PI, Araki M, Shariat SF (2025) Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: A systematic review and Meta-analysis of randomized controlled trials. Eur Urol Open Sci 73:31\u201342 PMID: 39935942; PMCID: PMC11810703","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"2583_CR41","first-page":"709","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43(5):709\u2013723","journal-title":"Arch Surg"},{"issue":"5","key":"2583_CR42","first-page":"950","volume":"87","author":"BH Han","year":"2013","unstructured":"Han BH, Lim JS, Kim SW (2013) Low-dose radiotherapy in the treatment of gynecomastia induced by antiandrogen therapy. Int J Radiat Oncol Biol Phys 87(5):950\u2013956","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2583_CR43","first-page":"855","volume":"11","author":"RJ Santen","year":"2010","unstructured":"Santen RJ, Mansel R, Goldstein L (2010) The role of aromatase inhibitors in gynecomastia prevention. Lancet Oncol 11(10):855\u2013864","journal-title":"Lancet Oncol"},{"issue":"2","key":"2583_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","volume":"57","author":"D Bedognetti","year":"2010","unstructured":"Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A, Boccardo F (2010) An open, randomised, multicentre, phase 3 trial comparing the efficacy of two Tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 57(2):238\u2013245. https:\/\/doi.org\/10.1016\/j.eururo.2009.05.019Epub 2009 May 19. PMID: 19481335","journal-title":"Eur Urol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02583-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02583-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02583-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:39:25Z","timestamp":1757158765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02583-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2583"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02583-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no financial interests.\u00a0Marco Giorgio Baroni and Arcangelo Barbonetti are members of the Editorial Board of the J Endocrinol Invest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}